The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction
Open accessAbstract
Summary: Background: Major classes of medical therapy for heart failure with reduced ejection fraction (HFrEF) induce reverse remodeling. The revere remodeling response to sacubitril/valsartan remains unstudied. Methods: We performed a single‐center, prospective assessor‐blinded study to determine the reverse remodeling response of sacubitril/valsartan therapy in HFrEF patients with a class I indication (New York heart Association [NYHA]‐class II‐IV, Left ventricular ejection fraction [LVEF] < 35%, optimal dose with Renin‐Angiotensin‐System‐Blocker [RAS‐blocker]). Doses of sacubitril/valsartan were optimized to individual tolerance. Echocardiographic images were assessed offline by 2 investigators blinded to both the clinical data and timing of echocardiograms. Results: One‐hundred‐twenty‐five HFrEF patients (66 ± 10 years) were prospectively included. The amount of RAS‐blocker before and after switch to sacubitril/valsartan was similar(P = .290), indicating individual optimal dosing of sacubitril/valsartan. Over a median(IQR) follow‐up of 118(77‐160) days after initiation of sacubitril/valsartan, LVEF improved (29.6 ± 6% vs 34.8 ± 6%; P < .001) and Left ventricular end‐systolic (LVESV) and end‐diastolic volume (LVEDV) decreased (LVESV; 147 ± 57 mL vs 129 ± 55 mL; P < .001 and LVEDV; 206 ± 71 mL vs197 ± 72 mL; P = .027). Volumetric remodeling was associated with a reduction in the degree of mitral regurgitation (1.59 ± 1.0 vs 1.11 ± 0.8; P < .001; [scale from 0‐4]). Metrics of diastolic function improved; including a drop in the E/A‐wave ratio (1.75 ± 1.13 vs 1.38 ± 0.88; P = .002) and diastolic filling time (% of cycle length) prolonged (48 ± 9% vs 52 ± 1%; P = .005). The percent of patients with a restrictive mitral filling pattern dropped from 47% to 23% (P = .004). A dose‐dependent effect was noted for changes in LVEF (P < .001) and LVESV (P = .031), with higher doses of sacubitril/valsartan leading to more reverse remodeling. Conclusion: Switching therapy in eligible HFrEF patients from a RAS‐blocker to sacubitril/valsartan induces beneficial reverse remodeling of both metrics of systolic as diastolic function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
The SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029
Angiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
Cited by
Proportionate and Disproportionate Functional Mitral Regurgitation
Grayburn, P. A., Sannino, A., & Packer, M. (2019) · JACC: Cardiovascular Imaging · doi:10.1016/j.jcmg.2018.11.006 · Cited by 651
Januzzi, J. L., Prescott, M. F., Butler, J., Felker, G. M., Maisel, A. S., McCague, K., Camacho, A., Piña, I. L., Rocha, R. A., Shah, A. M., et al. (2019) · JAMA · doi:10.1001/jama.2019.12821 · Cited by 634
Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation: PRIME Study
Kang, D.-H., Park, S.-J., Shin, S.-H., Hong, G.-R., Lee, S., Kim, M.-S., Yun, S.-C., Song, J.-M., Park, S.-W., & Kim, J.-J. (2019) · Circulation · doi:10.1161/circulationaha.118.037077 · Cited by 340
Wang, Y., Zhou, R., Lu, C., Chen, Q., Xu, T., & Li, D. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.012272 · Cited by 243
Metadata
- Authors
- Martens, P., Beliën, H., Dupont, M., Vandervoort, P., & Mullens, W.
- Venue
- Cardiovascular Therapeutics
- Publisher
- Wiley
- Published
- 2018-06-07
- Volume
- 36
- Issue
- 4
- Pages
- e12435-e12435
- ISSN
- 1755-5914 (ISSN-L)
- 1755-5922
- OpenAlex
- W2805015756
- Cited by
- 179
- References
- 4
- FWCI
- 14.80
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction. https://app.cochat.ai/papers/10.1111/1755-5922.12435
- The paper
- Martens, P., Beliën, H., Dupont, M., Vandervoort, P., & Mullens, W. (2018). The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction. Cardiovascular Therapeutics. https://doi.org/10.1111/1755-5922.12435
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.